Latest Licensing News

Dataworks Group Limited reported a modest revenue increase and a reduced net loss for FY25, underpinned by major contract wins in Canada and Australia. The company is targeting cashflow positivity in the first half of FY26 following operational efficiencies and capital raises.

Bougainville Copper Limited posted a deeper half-year loss as it ramps up exploration and navigates ongoing legal disputes tied to its historic Panguna mine. The company also advances infrastructure remediation under a key government agreement.

Cambium Bio reported a $3.84 million loss for FY25 but secured critical FDA approvals and ethics clearances to initiate Phase 3 trials of Elate Ocular®, supported by a $2.12 million capital raise.

Firebrick Pharma reported a substantial increase in Nasodine Nasal Spray revenues in FY25, alongside a widening net loss driven by reduced R&D incentives and increased marketing investments. The company is advancing its international rollout with new licensing deals and board appointments.

Iris Cairns Property Pty Ltd has lodged a bidder’s statement for an all-cash $3.87 per unit takeover offer for Reef Casino Trust, securing unanimous recommendation from the trust’s board and major unitholders. The offer, representing a significant premium, awaits regulatory approvals and closes in March 2026.

Streamplay Studio’s FY25 preliminary results reveal a striking 121% income surge, driven by the strategic acquisition of North American game studio Noodlecake, positioning the company for a $10 million annual income trajectory.

Cycliq Group Limited reported a 3.8% revenue increase to AUD 4.78 million for FY2025 alongside a significant reduction in net loss, driven by strategic product enhancements and a new AI partnership. The company also strengthened its board and launched a revamped e-commerce platform, positioning itself for growth despite ongoing legal and operational risks.

Streamplay Studio Limited reported a remarkable 201% surge in operating revenue for FY25, driven by its strategic acquisition of Noodlecake Studios and expansion into new markets. Despite a wider operating loss, the company achieved positive cash flow and profitability in the final quarter, signaling a promising turnaround.

Patrys Limited reported a 14.9% reduction in net loss for FY2025, driven by lower R&D expenses and tax incentives, while impairing key PAT-DX1 assets and shifting focus to PAT-DX3 development.

Vinyl Group Ltd reports a striking 190% revenue increase in FY25, driven by acquisitions and organic growth, while preparing for its first EBITDA positive quarter by December 2025.

Neurotech International reported a 23% revenue drop and a doubling of its net loss to $10.6 million for FY25, driven by reduced R&D grants and high development costs. Despite financial pressures, the company marked significant clinical and regulatory progress for its NTI164 cannabinoid therapy.

Orthocell Ltd reported a record $9.23 million revenue for FY25, driven by strong sales of its nerve repair and dental products, alongside securing US FDA clearance for its flagship nerve repair device Remplir. The company is poised for accelerated growth as it expands its global commercial footprint.